low - Rare genetic disease treatment demand is non-discretionary and insulated from economic cycles. Patients with severe genetic obesity disorders require continuous therapy regardless of macroeconomic conditions. However, payer budget constraints during recessions could marginally delay coverage approvals or increase prior authorization hurdles. Revenue is more sensitive to clinical adoption rates and genetic testing penetration than GDP fluctuations.

Rising rates negatively impact valuation multiples for pre-profitable biotechs as investors discount future cash flows more heavily and rotate toward current income. Higher rates increase cost of capital for potential debt financing and make equity raises more dilutive. However, Rhythm's $320M+ cash position (4.75x current ratio) provides 3-4 year runway, reducing near-term financing pressure. Rate sensitivity is primarily valuation-driven rather than operational.

growth - Attracts biotech growth investors focused on rare disease commercial execution and label expansion optionality. The 78% one-year return and 39x price-to-sales multiple reflect momentum-driven positioning rather than value characteristics. Negative profitability and high cash burn deter income and value investors. Institutional ownership likely concentrated among healthcare-focused funds with rare disease expertise and tolerance for binary clinical/regulatory risk.